BioNTech SE (BNTX) Revenue & Revenue Breakdown
BioNTech SE Revenue Highlights
Latest Revenue (Y)
$3.82B
Latest Revenue (Q)
$187.60M
Main Segment (Y)
Other Sales
Main Geography (Y)
UNITED STATES
BioNTech SE Revenue by Period
BioNTech SE Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $3.82B | -77.94% |
| 2022-12-31 | $17.31B | -8.78% |
| 2021-12-31 | $18.98B | 3834.42% |
| 2020-12-31 | $482.32M | 344.17% |
| 2019-12-31 | $108.59M | -14.88% |
| 2018-12-31 | $127.58M | 107.11% |
| 2017-12-31 | $61.60M | - |
BioNTech SE generated $3.82B in revenue during NA 2023, up -77.94% compared to the previous quarter, and up 2993.53% compared to the same period a year ago.
BioNTech SE Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $187.60M | -87.32% |
| 2023-12-31 | $1.48B | 65.20% |
| 2023-09-30 | $895.30M | 433.87% |
| 2023-06-30 | $167.70M | -86.87% |
| 2023-03-31 | $1.28B | -70.15% |
| 2022-12-31 | $4.28B | 23.61% |
| 2022-09-30 | $3.46B | 8.28% |
| 2022-06-30 | $3.20B | -49.86% |
| 2022-03-31 | $6.37B | 15.22% |
| 2021-12-31 | $5.53B | -9.11% |
| 2021-09-30 | $6.09B | 14.67% |
| 2021-06-30 | $5.31B | 159.15% |
| 2021-03-31 | $2.05B | 492.98% |
| 2020-12-31 | $345.44M | 412.08% |
| 2020-09-30 | $67.46M | 61.53% |
| 2020-06-30 | $41.76M | 50.97% |
| 2020-03-31 | $27.66M | -1.16% |
| 2019-12-31 | $27.99M | -2.35% |
| 2019-09-30 | $28.66M | 11.16% |
| 2019-06-30 | $25.79M | -1.41% |
| 2019-03-31 | $26.15M | -58.99% |
| 2018-12-31 | $63.78M | 212.69% |
| 2018-09-30 | $20.40M | - |
BioNTech SE generated $187.60M in revenue during Q1 2024, up -87.32% compared to the previous quarter, and up 4.38% compared to the same period a year ago.
BioNTech SE Revenue Breakdown
BioNTech SE Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| Other Sales | $319.00M | - | - | - | - |
| Research And Development | - | $3.50M | $116.00M | $102.70M | $178.85M |
| Commercial | - | $3.82B | $17.19B | $18.87B | $303.48M |
| Other Sales Transactions | - | - | - | - | $33.00M |
Latest
BioNTech SE's latest annual revenue breakdown by segment (product or service), as of Dec 24: Other Sales (100.00%).
BioNTech SE Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 24 | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|---|
| UNITED STATES | $1.85B | $3.01B | $12.71B | $14.64B | - |
| GERMANY | $706.90M | $482.70M | $2.24B | $20.60M | - |
| Rest of the World | $196.40M | - | - | - | - |
| DELAWARE | - | - | $3.03B | - | - |
Latest
BioNTech SE's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (67.17%), GERMANY (25.70%), and Rest of the World (7.14%).
BioNTech SE Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BNTX | BioNTech SE | $3.82B | $187.60M |
| SRPT | Sarepta Therapeutics | $1.90B | $362.93M |
| PTCT | PTC Therapeutics | $806.78M | $135.42M |
| NVAX | Novavax | $682.16M | $415.48M |
| KRYS | Krystal Biotech | $290.51M | $83.84M |
| DNA | Ginkgo Bioworks | $227.04M | $89.05M |
| MDGL | Madrigal Pharmaceuticals | $180.13M | $62.17M |
| IOVA | Iovance Biotherapeutics | $164.07M | $58.55M |
| CRSP | CRISPR Therapeutics | $37.31M | $602.00K |
| OCEA | Ocean Biomedical | - | - |
| HEPA | Hepion Pharmaceuticals | - | - |
| ELEV | Elevation Oncology | - | - |
| ENVB | Enveric Biosciences | - | - |